Bright Minds Biosciences (DRUG) Profit After Tax (2020 - 2026)

Bright Minds Biosciences' Profit After Tax history runs 7 years deep, the most recent figure standing at $20.8 million for Q1 2026.

• Quarterly Profit After Tax changed N/A year-over-year to $20.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.1 million (changed N/A YoY) and the FY2025 annual result came in at -$8.9 million, down 332.64% from the prior year.
• Profit After Tax was $20.8 million for Q1 2026 at Bright Minds Biosciences, up from -$3.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at $20.8 million in Q1 2026 and bottomed at -$20.7 million in Q3 2022.
• A 5-year average of -$859157.0 and a median of $35513.3 in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2022 — Profit After Tax jumped 183.21% — and 2025, when it slumped 2351.11%.
• Bright Minds Biosciences' Profit After Tax stood at $1.7 million in 2022, then sank by 171.91% to -$1.2 million in 2023, then soared by 102.87% to $35513.3 in 2024, then slumped by 8459.53% to -$3.0 million in 2025, then soared by 799.66% to $20.8 million in 2026.
• Business Quant data shows DRUG's Profit After Tax at $20.8 million in Q1 2026, -$3.0 million in Q3 2025, and -$3.8 million in Q2 2025.